NCT00730223View on ClinicalTrials.gov

Genetic Determinants of the Metabolism of Non-nucleoside Reverse Transcriptase Inhibitors

PHASE1CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

March 31, 2004

Primary Completion Date

March 31, 2006

Study Completion Date

August 31, 2009

Conditions
HIV Infections
Interventions
DRUG

Nevirapine and Efavirenz

single oral dose 200mg of nevirapine and single oral dose 600 mg of efavirenz

All Listed Sponsors
lead

Vanderbilt University

OTHER

NCT00730223 - Genetic Determinants of the Metabolism of Non-nucleoside Reverse Transcriptase Inhibitors | Biotech Hunter | Biotech Hunter